Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

JOHNSON & JOHNSON

(JNJ)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies
Analyst Recommendations on JOHNSON & JOHNSON
06/01JOHNSON & JOHNSONá : Credit Suisse reiterates its Buy rating
MD
05/31TODAY'S ANALYST RECOMMENDATIONS : Advanced Micro Devices, AstraZeneca, Bodycote,..
05/28JOHNSON & JOHNSONá : Morgan Stanley Assumes Johnson & Johnson at Overweight with..
MT
01/28JOHNSON & JOHNSONá : DA Davidson Adjusts Price Target on Johnson & Johnson to $1..
MT
01/27JOHNSON & JOHNSONá : UBS Adjusts Johnson & Johnson's Price Target to $180 From $..
MT
01/27JOHNSON & JOHNSONá : SVB Leerink Adjusts Johnson & Johnson's Price Target to $20..
MT
01/27JOHNSON & JOHNSONá : Morgan Stanley Adjusts Johnson & Johnson's Price Target to ..
MT
01/27JOHNSON & JOHNSONá : Cowen Adjusts Johnson & Johnson's Price Target to $195 From..
MT
01/27JOHNSON & JOHNSONá : Raymond James Adjusts Johnson & Johnson's Price Target to $..
MT
01/27JOHNSON & JOHNSONá : Cantor Fitzgerald Adjusts Johnson & Johnson's Price Target ..
MT
01/27JOHNSON & JOHNSONá : Credit Suisse Adjusts Johnson & Johnson's Price Target to $..
MT
01/27JOHNSON & JOHNSONá : Stifel Nicolaus Adjusts Price Target for Johnson & Johnson ..
MT
01/27JOHNSON & JOHNSONá : Goldman Sachs Adjusts Price Target for Johnson & Johnson to..
MT
01/27JOHNSON & JOHNSONá : JP Morgan Adjusts Price Target for Johnson & Johnson to $17..
MT
01/27JOHNSON & JOHNSONá : Wells Fargo Adjusts Johnson & Johnson's Price Target to $19..
MT
01/20JOHNSON & JOHNSONá : UBS Adjusts Price Target on Johnson & Johnson to $170 From ..
MT
2020JOHNSON & JOHNSONá : Zacks Adjusts Johnson & Johnson's Price Target to $161 from..
MT
2020JOHNSON & JOHNSONá : Morgan Stanley Adjusts Price Target for Johnson & Johnson t..
MT
2020JOHNSON & JOHNSONá : Credit Suisse gives a Buy rating
MD
2020J&J, Biotech Firm In $6.5 Billion Deal J&J Agrees to Buy Biotech Company -- W..
DJ
2020Pharma Companies Split on Coronavirus Vaccine Pricing Plans
DJ
2020JOHNSON & JOHNSONá : Beats Analysts' Profit Expectations for 2Q
DJ
2020GENMABá : Darzalex Meets Main Endpoint in Light-Chain Amyloidosis Study
DJ
2020Drugmakers see long road ahead in coronavirus vaccine race
RE
2019J&J recalls 33,000 bottles of baby powder as FDA finds asbestos in sample
RE
2019JOHNSON & JOHNSONá : Goldman Sachs maintains a Buy rating
MD
2019JOHNSON & JOHNSONá : Credit Suisse reiterates its Buy rating
MD
2019JOHNSON & JOHNSONá : J&J warns of hit from generic drugs in third quarter, share..
RE
2019JOHNSON & JOHNSONá : J&J warns of hit from generic drugs in third quarter, share..
RE
2019JOHNSON & JOHNSONá : Credit Suisse keeps its Buy rating
MD
2019JOHNSON & JOHNSONá : RBC reaffirms its Buy rating
MD
2019GLOBAL MARKETS LIVE : LVMH, Burberry, Facebook, Teslaů
2019Bristol-Myers plans to divest Celgene's psoriasis drug, shares slide
RE
2019Biogen scraps two Alzheimer drug trials, wipes $18 billion from market value
RE
2019Emerging markets to fuel Smith & Nephew revenue growth in 2019
RE
2018Biotech incubator taps investors through in-house brokerage
RE
2018U.S. insurers grilled on exposure to $4.7 billion J&J talc verdict
RE
2018J&J nears diabetes device exit with $2.1 bln LifeScan sale
RE
2018Johnson & Johnson nears diabetes device exit with $2.1 billion LifeScan sale
RE
2018Sanofi beats Novo to buy Ablynx for $4.8 billion in biotech M&A boom
RE
2018Sanofi digs deep to buy U.S. haemophilia group Bioverativ for $11.6 billion
RE
2018Sanofi digs deep to buy U.S. haemophilia group Bioverativ for $11.6 billion
RE
2018Sanofi digs deep to buy U.S. haemophilia group Bioverativ for $11.6 billion
RE
2017European shares reverse early losses, DAX immune to political worries
RE
2017FTSE weighed down by housebuilders and strong pound
RE
2017U.S. dollar up, yield curve flat, on inflation; stocks rise
RE
2017U.S. dollar up, yield curve flat, on inflation; stocks rise
RE
2017Germany's Merck hires JP Morgan to sell consumer health
RE
2017Nestle plan hailed as only the start of Schneider's shake-up
RE
2017Nestle plan hailed as only the start of Schneider's shake-up
RE
2017Stroke drug Xarelto, plastics lift Bayer earnings
RE
2017Morgan Stanley bags big spots on Unilever, Reckitt deals - sources
RE
2017Johnson & Johnson refills drug cabinet with $30 billion Actelion deal
RE
2017Japan's Takeda ready for fresh acquisitions after $5.2 billion Ariad deal
RE
2016Pfizer to start shipping biosimilar version of J&J's Remicade in November
RE
2016Moody's reviews Microsoft credit rating for cut after LinkedIn deal
RE
2016Cheap oil smudges Exxon's long-held sterling credit rating
RE
2016No quick fix seen for Novartis's troubled Alcon unit
RE
2015Big business on winning side in U.S. top court's major rulings
RE
2015CELLTRIONá : J&J cuts full-year forecast due to strong dollar
RE
2015AbbVie CEO defends Pharmacyclics deal to sceptical investors
RE
2015Cardinal to buy J&J vascular technology unit Cordis for $1.9 billion
RE
2014Johnson Matthey optimistic for full-year
RE
2014Sodexo cuts sales growth forecast due to contract delays
RE
2014Bayer wins Merck & Co's $14 billion consumer unit auction
RE
2014Bayer wins Merck & Co's $14 billion consumer unit auction
RE
2014Johnson Matthey says outlook brighter, names new CEO
RE
2013Factbox - U.S. biotech shares outpace broader stock market
RE
2013Elan rejects Royalty bid as grossly undervaluing its prospects
RE
2013Elan rejects Royalty bid as grossly undervaluing its prospects
RE
2013Ahead of reform, medical care slowdown hits companies
RE
2013Analysis - Ahead of reform, medical care slowdown hits U.S. companies
RE
2013J&J stake sale clouds Royalty bid for Elan
RE
2013Elan bid to fend off Royalty handed boost in buyback
RE
2013Elan offers special dividend to fend off Royalty
RE
1  2Next
Upcoming event on JOHNSON & JOHNSON